1-14 of 14
Pamela Bacon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety Profile for Lenalidomide-Based and Non-Lenalidomide-Based First-Line Therapy for Multiple Myeloma in Transplant Ineligible Patients: Real-World Evidence from a European Post-Authorization Safety Study

Michele Cavo, Valerio De Stefano, MD, Angel Ramirez Payer, Martin Wiesholzer, Yvonne Tromp, Gaëtan Vanstraelen, Baerbel Schaedlich, Richez Valentine, Sujith Dhanasiri, Elisabeth Kueenburg, Barbara Rosettani, Claire Martin, Stefano Pozzi, Pamela Bacon, Barbara Gamberi
Journal: Blood
Blood (2019) 134 (Supplement_1): 5580.
https://doi.org/10.1182/blood-2019-124555
Published: 2019
Journal Articles

Safety in Patients with Multiple Myeloma Treated with Pomalidomide in a Real-World Setting According to Last Prior Treatment: A European Post-Authorization Safety Study

Niels Abildgaard, MD PhD, Marie-Christiane Vekemans, Barbara Gamberi, MD, Francesco Di Raimondo, MD, Angel Ramirez Payer, Charalampia Kyriakou, Alain Kentos, Elisabeth Kueenburg, Antonia Di Micco, Barbara Rosettani, Pamela Bacon, Margaret Atiba-Davies, Torben Plesner, MD DSc
Journal: Blood
Blood (2018) 132 (Supplement 1): 3286.
https://doi.org/10.1182/blood-2018-99-111906
Published: 2018
Journal Articles

MM-013 Phase 2, Multicenter Study of Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): Pharmacokinetics (PK) Analysis

Pieter Sonneveld, MDPhD, Katja C. Weisel, Yan Li, Elisabeth Kueenburg, Shona Collins, Antonia Di Micco, Barbara Rosettani, Pamela Bacon, Meletios A. Dimopoulos
Journal: Blood
Blood (2017) 130 (Supplement 1): 1847.
https://doi.org/10.1182/blood.V130.Suppl_1.1847.1847
Published: 2017
Journal Articles

European Post-Approval Safety Study (Registry) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety of Patients Treated with Pomalidomide

Francesco Di Raimondo, Charalampia Kyriakou, Martin Schmidt-Hieber, Marie-Christiane Vekemans, Ángel Ramírez Payer, Pal Tore Bentsen, Birgitta Lauri, Elisabeth Kueenburg, Frederik Lersch, Barbara Rosettani, Pamela Bacon, Torben Plesner, Professor
Journal: Blood
Blood (2016) 128 (22): 5680.
https://doi.org/10.1182/blood.V128.22.5680.5680
Published: 2016
Journal Articles

European Post-Approval Safety Study (PASS) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including SPM, in a Large Cohort of Patients Treated with Lenalidomide, Thalidomide, and Bortezomib

Barbara Gamberi, Miguel Hernandez, Christian Berthou, Eleni Tholouli, Elena Zamagni, Roman Hájek, Monique Minnema, Meletios A Dimopoulos, Jo Caers, Niels Frost Andersen, Bjorn Andreasson, Anders Waage, MD PhD, Gerard Crotty, Elisabeth Kueenburg, Barbara Rosettani, Antonia Di Micco, Pamela Bacon, Igor Blau
Journal: Blood
Blood (2016) 128 (22): 3331.
https://doi.org/10.1182/blood.V128.22.3331.3331
Published: 2016
Journal Articles

Safety Results of a Phase 2 Multicenter, Open-Label Study of Pomalidomide (CC-4047) Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment

Katja Weisel, MD, Meletios A Dimopoulos, Niels W.C.J. van de Donk, MD PhD, Karthik Ramasamy, Barbara Gamberi, Matthew Streetly, Massimo Offidani, Frank Bridoux, Javier de la Rubia, Elisabeth Kueenburg, Frederik Lersch, Barbara Rosettani, Pamela Bacon, Pieter Sonneveld
Journal: Blood
Blood (2016) 128 (22): 3311.
https://doi.org/10.1182/blood.V128.22.3311.3311
Published: 2016
Journal Articles

Health-Related Quality of Life in Lenalidomide and Bortezomib Treated Patients with Relapsed/Refractory Multiple Myeloma

Charalampia Kyriakou, MD PhD, Philip Murphy, MD, Maria Teresa Petrucci, MD, Pamela Bacon, Philip Lewis, Hélène Gilet, MSc, Benoit Arnould, PhD, Isabelle Vande Broek, MD PhD, Xavier Leleu, MD
Journal: Blood
Blood (2015) 126 (23): 2085.
https://doi.org/10.1182/blood.V126.23.2085.2085
Published: 2015
Journal Articles

Safety of Treatment (Tx) with Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI), Including Those on Dialysis

Karthik Ramasamy, Meletios A. Dimopoulos, Niels W.C.J. van de Donk, Barbara Gamberi, Frank Bridoux, Matthew Streetly, Elisabeth Kueenburg, Barbara Rosettani, Shona Collins, Frederik Lersch, Pamela Bacon, Katja C. Weisel, Pieter Sonneveld, MD PhD
Journal: Blood
Blood (2015) 126 (23): 374.
https://doi.org/10.1182/blood.V126.23.374.374
Published: 2015
Journal Articles

Continued Treatment Duration, Drug dosing  and Health-Related Quality Of Life (HRQoL) Of Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Receiving 2 nd and 3 rd Line Treatments: Results From a European Multicentre Study

Maria Teresa Petrucci, MD, Xavier Leleu, MD, PhD, Charalampia Kyriakou, Isabelle Vande Broek, PhD, Philip T Murphy, MD, MRCPath, Philip Lewis, PhD, Pamela Bacon, Benoit Arnould, PhD, Manfred Welslau
Journal: Blood
Blood (2013) 122 (21): 5368.
https://doi.org/10.1182/blood.V122.21.5368.5368
Published: 2013
Journal Articles

Psychometric Performance Of The EORTC Quality-Of-Life Core Questionnaire (QLQ-C30) and QLQ-Multiple Myeloma (QLQ-MY20) In Relapsed/Refractory Multiple Myeloma (RRMM)

Xavier Leleu, MD, PhD, Maria Teresa Petrucci, MD, Manfred Welslau, Isabelle Vande Broek, Philip T Murphy, MD, MRCPath, Andrew Bottomley, PhD, Pamela Bacon, Philip Lewis, PhD, Hélène Gilet, MSc, Benoit Arnould, PhD, Charalampia Kyriakou
Journal: Blood
Blood (2013) 122 (21): 1721.
https://doi.org/10.1182/blood.V122.21.1721.1721
Published: 2013
Journal Articles

Post-Approval Safety Study (PASS) of Lenalidomide Compared with Other Treatments in Patients with Relapsed or Refractory Multiple Myeloma

Michele Cavo, MD, Luciano Masini, Igor W. Blau, Miguel T. Hernandez, Renato Zambello, Paolo de Fabritiis, Christian Berthou, Argiris Symeonidis, Jennifer Bird, Javier De La Rubia, Pamela Bacon, Barbara Rosettani, Elisabeth Kueenburg, Neil Minton
Journal: Blood
Blood (2011) 118 (21): 1867.
https://doi.org/10.1182/blood.V118.21.1867.1867
Published: 2011
Journal Articles

Febrile Neutropenia Risk Assessment and Granulocyte-Colony Stimulating Factor Support in Patients with Diffuse Large B Cell Lymphoma Receiving R-CHOP Regimens.

Antonio Salar, MD, PhD, Corinne Haioun, MD, Francesca Gaia Rossi, MD, Ulrich Duehrsen, MD, Ruth Pettengell, Hans Erik Johnsen, MD, Ulrich Jaeger, MD, Gregor Verhoef, Matthias Schwenkglenks, PhD, Fernando Principe, MD, Pamela Bacon, PhD, Kate Bendall, P.J. Lugtenburg, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 107.
https://doi.org/10.1182/blood.V114.22.107.107
Published: 2009
Journal Articles

Pegfilgrastim Supports Delivery of BEACOPP Chemotherapy Administered Every 14 Days.

Andreas Engert, Hartmut Doehner, Anthony D. Ho, Norbert Schmitz, Henning Bredenfeld, Dieter Hoelzer, Beate Klimm, Axel Muenz, Valerie Easton, Pamela Bacon, Volker Diehl
Journal: Blood
Blood (2004) 104 (11): 1316.
https://doi.org/10.1182/blood.V104.11.1316.1316
Published: 2004
Journal Articles

Pegfilgrastim Supports Delivery of CHOP-R Chemotherapy Administered Every 14 Days: A Randomised Phase II Study.

Andres Lopez, Alberto Fernandez de Sevilla, Sylvie Castaigne, Richard Greil, Jorge Sierra, Jordi Sanchez, Valerie Easton, Pamela Bacon
Journal: Blood
Blood (2004) 104 (11): 3311.
https://doi.org/10.1182/blood.V104.11.3311.3311
Published: 2004